Pharmexa and Affitech entered into a license agreement related to a single-chain bi-specific antibody, or diabody, technology.
"Because of the built-in dual specificity,” notes Affitech CEO, Martin Welschof, Ph.D., “diabodies are extremely interesting in the field of cancer research. Therefore, we see them as having great potential in our chosen field of oncology therapeutics.”
Under the terms of the worldwide, exclusive license deal, Affitech gained rights to certain Pharmexa intellectual property on these recombinant antibody-like proteins. The company may conduct IND-enabling research activities.
Affitech also signed a promotion collaboration to sub-license the intellectual property rights to other companies to conduct relevant activities leading to the manufacturing and commercialization of licensed products. Pharmexa and Affitech will share all proceeds from such third party agreements.
“We have built up comprehensive knowledge about the other relevant players in the antibody field of research and development likely to be interested in taking out a license for the development, manufacturing, and commercialization of Diabodies", adds Dr. Welschof.